In a recent development, Moderna announced that the U.S. FDA has halted a late-stage trial of its experimental norovirus vaccine, mRNA-1403, following a reported case of Guillain-Barre syndrome, a rare neurological side effect. The company emphasized that the adverse event is being thoroughly investigated, and the causal relationship between the vaccine and the syndrome is yet to be determined.
During a conference call, a Moderna executive shared that the reported Guillain-Barre case occurred shortly after vaccine administration, adding complexity to establishing a definitive cause-effect correlation. The FDA has initiated a review of the submitted materials, with the possibility of seeking clarification from the company.
Despite the clinical hold, Moderna assured that completion of enrollment in the Northern Hemisphere for the norovirus vaccine trial has concluded, with no expected delays in enrollment for the Southern Hemisphere. The company, which has been aiming to diversify its revenue sources post-pandemic, faced challenges as demand for COVID-19 vaccines decreased and uptake of its RSV vaccine fell short of projections last year.
Modern's financial results for the fourth quarter indicated a substantial decline in revenue, primarily attributed to lower COVID shot sales. The company reported an unexpected quarterly loss per share, driven by a non-cash charge related to terminating an agreement with a contract manufacturer. To counteract the revenue decline, Moderna announced cost-cutting measures, aiming to reduce cash costs by $1 billion in addition to another $500 million by 2026.
The company remains focused on optimizing its manufacturing footprint and cost efficiency, as evidenced by scaling down Spikevax COVID-19 vaccine production and reducing cost of sales significantly in 2023. Despite challenges, Moderna expressed confidence in the long-term potential of its RSV market and reiterated its full-year 2025 product sales forecast of $1.5 billion to $2.5 billion, with the bulk of revenue anticipated in the latter half of the year.
Although facing setbacks with the paused norovirus vaccine trial, Moderna is strategically navigating challenges to sustain its market presence and drive future growth in the evolving landscape of vaccine development and distribution.